Results 11 to 20 of about 189,087 (191)

Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration [PDF]

International Journal of Retina and Vitreous, 2021
Background To assess the morphological and functional outcome of intravitreal aflibercept following the treat and extend protocol compared to the fixed protocol for treatment of eyes with neovascular age-related macular degeneration.
Alaa Din Abdin, Asem Mohamed, Cristian Munteanu, Isabel Weinstein, Achim Langenbucher, Berthold Seitz, Shady Suffo   +6 more
doaj   +2 more sources

A simulation tool for better management of retinal services [PDF]

BMC Health Services Research, 2018
Background Advances in the management of retinal diseases have been fast-paced as new treatments become available, resulting in increasing numbers of patients receiving treatment in hospital retinal services. These patients require frequent and long-term
Eren Demir, David Southern, Aimee Verner, Winfried Amoaku   +3 more
doaj   +4 more sources

Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema [PDF]

Scientific Reports, 2021
AbstractThis prospective, open-label, single-arm, non-randomized clinical trial, assessed the efficacy of a 2-year treat-and-extend (T&E) regimen involving intravitreal aflibercept injection (IAI), with the longest treatment interval set to 16 weeks, and adjunct focal/grid laser in diabetic macula edema (DME) patients.
Takao Hirano, Yuichi Toriyama, Yoshihiro Takamura, Masahiko Sugimoto, Taiji Nagaoka, Yoshimi Sugiura, Fumiki Okamoto, Michiyuki Saito, Kousuke Noda, Shigeo Yoshida, Akihiro Ishibazawa, Osamu Sawada, Toshinori Murata   +12 more
openaire   +6 more sources

Faricimab Treat-and-Extend for Diabetic Macular Edema [PDF]

Ophthalmology
Purpose: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-andextend (T&E)-based regimen with up to every-16-week dosing in the YOSEMITE and RHINE (ClinicalTrials.govidentifiers, NCT03622580 and ...
WONG, T, YOSEMITE AND RHINE INVESTIGATORS, YOSEMITE and RHINE Investigators   +2 more
core   +5 more sources

Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment [PDF]

Scientific Reports
We evaluated the incidence and risk factors for recurrence in patients with neovascular age-related macular degeneration (nAMD) who discontinued anti-vascular endothelial growth factor (VEGF) therapy under a modified treat-and-extend (TAE) protocol.
Junwoo Lee, Jaehwan Choi, Seung-Young Yu, Kiyoung Kim   +3 more
doaj   +2 more sources

Five-year outcome of aflibercept intravitreal injection in naïve patients with neovascular age-related macular degeneration using a modified treat-and-extend regimen: Results from a prospective observational study [PDF]

Taiwan Journal of Ophthalmology, 2023
PURPOSE: The purpose is to study the 5-year results of aflibercept monotherapy using an individualized regimen in naïve patients with neovascular AMD (nAMD). MATERIALS AND METHODS: This is a prospective observational study including naïve nAMD patients
Jarret Charles, TRAN Thi Ha Chau
doaj   +2 more sources

Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice [PDF]

Ophthalmology and Therapy, 2019
Introduction Treat-and-extend (T&E) and pro re nata (PRN; ‘as needed’) regimens of intravitreal anti-vascular endothelial growth factor (VEGF) treatment have been found to reduce the injection burden on patients and improve the cost effectiveness of the ...
Beverley A. Curry, Paul G. Sanfilippo, Sarah Chan, Alexander W. Hewitt, Nitin Verma   +4 more
doaj   +4 more sources

Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up [PDF]

Clinical Ophthalmology
Taras B Kustryn, Oleg S Zadorozhnyy, Illia O Nasinnyk, Alla O Nevska, Kseniia V Troianovska, Nataliya V Pasyechnikova, Andrii R Korol Laser Microsurgery Department, The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of ...
Kustryn TB, Zadorozhnyy OS, Nasinnyk IO, Nevska AO, Troianovska KV, Pasyechnikova NV, Korol AR   +6 more
doaj   +2 more sources

Multicentric Cardiac Myxoma Treated with Extended Surgery [PDF]

Journal of International Medical Research, 2006
We present the case of a 37-year-old male patient with a multicentric myxoma admitted to hospital with dyspnoea, syncope and chest pain. Physical examination revealed a grade 3/6 systolic murmur at the left lower sternal border and diffuse bilateral lung rales.
Cengiz, M., Gurbuz, O., Yilmaz, M.
openaire   +3 more sources

GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration [PDF]

, 2016
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the ...
Altay, Lebriz, Baird, Paul N, Burdon, Kathryn Penelope, Chen, John, de Jong, Eiko K, den Hollander, Anneke I, Fauser, Sascha, Guymer, Robyn H, Hoyng, Carel B, Koenekoop, Robert K, Lores-Motta, Laura, Lu, Yi, MacGregor, Stuart, Montgomery, Grant W, Muether, Philipp, Omar, Amer, Riaz, Moeen, Richardson, Andrea J, Schick, Tina, Smailhodzic, Dzenita, van Asten, Freekje   +20 more
core   +14 more sources